NCT01928394 2024-12-27A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid TumorsBristol-Myers SquibbPhase 1/2 Completed1,163 enrolled 33 charts 1 FDA